Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.

Chung V, Mansfield AS, Braiteh F, Richards D, Durivage H, Ungerleider RS, Johnson F, Kovach JS.

Clin Cancer Res. 2017 Jul 1;23(13):3277-3284. doi: 10.1158/1078-0432.CCR-16-2299. Epub 2016 Dec 30.

2.

High time for low-dose prospective clinical trials.

DiPaola RS, Durivage HJ, Kamen BA.

Cancer. 2003 Oct 15;98(8):1559-61. No abstract available.

3.

A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix.

Irvin WP, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ, Potkul RK.

Cancer. 1998 Jan 15;82(2):328-33.

PMID:
9445190
4.

A phase I pilot study of BCNU plus thymidine in patients with refractory cancer.

Schultz MZ, Sandler AB, Durivage HJ, Cooper DL.

Cancer Invest. 1996;14(3):218-24.

PMID:
8630682
5.

Trifluoperazine as a modulator of multidrug resistance in refractory breast cancer.

Murren JR, Durivage HJ, Buzaid AC, Reiss M, Flynn SD, Carter D, Hait WN.

Cancer Chemother Pharmacol. 1996;38(1):65-70.

PMID:
8603454
6.

Cisplatin, doxorubicin, mitomycin C, and 5-fluorouracil for the treatment of metastatic non-small cell lung cancer. Limited activity of an aggressive chemotherapy regimen.

Murren JR, Durivage HJ, Rosenberg AH, Chen Y, Del Prete SA, Murphy GJ, Buzaid AC, Hait WN.

Am J Clin Oncol. 1994 Jun;17(3):239-41.

PMID:
8192110
7.

Cyclosporine treatment of refractory T-cell lymphomas.

Cooper DL, Braverman IM, Sarris AH, Durivage HJ, Saidman BH, Davis CA, Hait WN.

Cancer. 1993 Apr 1;71(7):2335-41.

PMID:
8453556
8.

A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.

Murren JR, Ganpule S, Papac R, Son YH, Peschel RE, Durivage H, Buzaid AC, Lamb L, Makuch R, Hait WN.

Oncol Res. 1993;5(2):53-7.

PMID:
8395915
9.

Phase II study of pulse 5-fluoro-2'-deoxyuridine and leucovorin in advanced colorectal cancer patients previously treated with chemotherapy.

Marsh JC, Durivage HJ, Davis C, O'Hollaren K, Pasquale DN, Simonich SA, Voynick IM, Bertino JR.

Am J Clin Oncol. 1992 Apr;15(2):115-8.

PMID:
1532470
10.

High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.

Buzaid AC, Murren JR, Durivage HJ.

Cancer. 1991 Sep 15;68(6):1238-41.

PMID:
1873775
11.

A phase II trial of cyclosporin A in the treatment of refractory metastatic colorectal cancer.

Murren JR, Ganpule S, Sarris A, Durivage H, Davis C, Makuch R, Handschumacher RE, Marsh JC.

Am J Clin Oncol. 1991 Jun;14(3):208-10.

PMID:
2031507
12.

High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.

Buzaid AC, Murren J, Durivage HJ.

Am J Clin Oncol. 1991 Jun;14(3):203-7.

PMID:
1851602
13.

High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.

Murren JR, DeRosa W, Durivage HJ, Davis C, Makuch R, Portlock CS.

Cancer. 1991 Mar 15;67(6):1514-7.

PMID:
2001539
14.

The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer.

Marsh JC, Bertino JR, Katz KH, Davis CA, Durivage HJ, Rome LS, Richards F 2nd, Capizzi RL, Farber LR, Pasquale DN, et al.

J Clin Oncol. 1991 Mar;9(3):371-80.

PMID:
1999706
15.

The effect of calmodulin inhibitors with bleomycin on the treatment of patients with high grade gliomas.

Hait WN, Byrne TN, Piepmeier J, Durivage HJ, Choudhury S, Davis CA, Gates JA.

Cancer Res. 1990 Oct 15;50(20):6636-40.

16.

Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine.

Hait WN, Morris S, Lazo JS, Figlin RJ, Durivage HJ, White K, Schwartz PE.

Cancer Chemother Pharmacol. 1989;23(6):358-62.

PMID:
2469543
17.

Metastatic breast cancer: preliminary results with oral hormonal therapy.

Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, Einhorn L, et al.

Semin Oncol. 1985 Dec;12(4 Suppl 6):61-4.

PMID:
3909420
18.

Anti-estrogen therapy for breast cancer: focus on tamoxifen.

Flynn KT, Durivage HJ.

Oncol Nurs Forum. 1982 Fall;9(4):21-5. No abstract available.

PMID:
6923414

Supplemental Content

Loading ...
Support Center